Citations (101)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Peter S. Lee, Katherine G. MacDonald, Evan Massi, Pamela V. Chew, Christine Bee, Padma Perkins, Bryant Chau, Kent Thudium, Jack Lohre, Pradyot Nandi, Ekaterina G. Deyanova, Ishita Barman, Olafur Gudmundsson, Gavin Dollinger, Tim Sproul, John J. Engelhardt, Pavel Strop & Arvind Rajpal. (2022) Improved therapeutic index of an acidic pH-selective antibody. mAbs 14:1.
Read now
Read now
Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang & Javier Chaparro-Riggers. (2022) Bispecific antibodies for immune cell retargeting against cancer. Expert Opinion on Biological Therapy 22:8, pages 965-982.
Read now
Read now
Yoji Murata, Yasuyuki Saito, Takenori Kotani & Takashi Matozaki. (2020) Blockade of CD47 or SIRPα: a new cancer immunotherapy. Expert Opinion on Therapeutic Targets 24:10, pages 945-951.
Read now
Read now
Sahana Kumar, Anujan Ramesh & Ashish Kulkarni. (2020) Targeting macrophages: a novel avenue for cancer drug discovery. Expert Opinion on Drug Discovery 15:5, pages 561-574.
Read now
Read now
Mark A. J. M. Hendriks, Emily M. Ploeg, Iris Koopmans, Isabel Britsch, Xiurong Ke, Douwe F. Samplonius & Wijnand Helfrich. (2020) Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. OncoImmunology 9:1.
Read now
Read now
Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Valéry Moine, Laurence Chatel, Lucile Broyer, Guillemette Pontini, Tereza Bautzova, Flora Juan, Sebastien Calloud, Nicolas Bosson, Maud Charreton, Krzysztof Masternak, Vanessa Buatois & Limin Shang. (2020) Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. mAbs 12:1.
Read now
Read now
Laahn H. Foster & Lawrence G. Lum. (2019) Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opinion on Biological Therapy 19:7, pages 707-720.
Read now
Read now
Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer & Wijnand Helfrich. (2018) A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. OncoImmunology 7:8.
Read now
Read now
Boning Liu, Huaizu Guo, Jin Xu, Ting Qin, Qingcheng Guo, Nana Gu, Dapeng Zhang, Weizhu Qian, Jianxin Dai, Sheng Hou, Hao Wang & Yajun Guo. (2018) Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. mAbs 10:2, pages 315-324.
Read now
Read now
Peter E. van Bommel, Yuan He, Ilona Schepel, Mark A. J. M. Hendriks, Valerie R. Wiersma, Robert J. van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F. Samplonius, Wijnand Helfrich & Edwin Bremer. (2018) CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. OncoImmunology 7:2.
Read now
Read now
Shiyong Gong, Fang Ren, Danqing Wu, Xuan Wu & Chengbin Wu. (2017) Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets. mAbs 9:7, pages 1118-1128.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Anke Steinmetz, François Vallée, Christian Beil, Christian Lange, Nicolas Baurin, Jochen Beninga, Cécile Capdevila, Carsten Corvey, Alain Dupuy, Paul Ferrari, Alexey Rak, Peter Wonerow, Jochen Kruip, Vincent Mikol & Ercole Rao. (2016) CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. mAbs 8:5, pages 867-878.
Read now
Read now
Articles from other publishers (88)
Pengcheng Zhao, Longyan Xie, Lei Yu & Ping Wang. (2024) Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy. Genes & Diseases 11:1, pages 205-217.
Crossref
Crossref
Xukai Luo, Yini Shen, Wu Huang, Yiting Bao, Jiahang Mo, Liangqing Yao & Lei Yuan. (2023) Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer. Cancer Control 30, pages 107327482311597.
Crossref
Crossref
Yun Yang, He Wu, Yan Yang, Yan Kang, Runjia He, Bei Zhou, Huaizu Guo, Jing Zhang, Jianqin Li, Chunpo Ge & Tianyun Wang. (2023) Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy. Molecular Therapy - Oncolytics 31, pages 100747.
Crossref
Crossref
Chao Wang, Ying Feng, Deepali Patel, Hongwei Xie, Yaqing Lv & Hai Zhao. (2023) The role of CD47 in non-neoplastic diseases. Heliyon 9:12, pages e22905.
Crossref
Crossref
Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu & Ming Yi. (2023) Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Yu Hao, Xinxuan Zhou, Yiling Li, Bolei Li & Lei Cheng. (2023) The CD47-SIRPα axis is a promising target for cancer immunotherapies. International Immunopharmacology 120, pages 110255.
Crossref
Crossref
Wenxi Xia, Neetu Singh, Shreya Goel & Sixiang Shi. (2023) Molecular imaging of innate immunity and immunotherapy. Advanced Drug Delivery Reviews 198, pages 114865.
Crossref
Crossref
Si-Yuan Li, Yong-Lin Guo, Jia-Wen Tian, He-Jing Zhang, Rui-Fang Li, Ping Gong & Zi-Li Yu. (2023) Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages. Cancers 15:10, pages 2717.
Crossref
Crossref
Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana Carvalho Santos, Pedro Blecua, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin, Francesc Bosch, Manel Esteller, Emmanuel Normant & Gael Roué. (2023) G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy. Frontiers in Immunology 14.
Crossref
Crossref
Julia Harwardt, Stefania C. Carrara, Jan P. Bogen, Katrin Schoenfeld, Julius Grzeschik, Björn Hock & Harald Kolmar. (2023) Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody. Frontiers in Immunology 14.
Crossref
Crossref
Hang Ke, Faming Zhang, Jingjing Wang, Lingxin Xiong, Xiaoyu An, Xiaolong Tu, Cen Chen, Yueying Wang, Binchen Mao, Sheng Guo, Cunxiang Ju, Xiangfei He, Ruilin Sun, Lei Zhang, Owen A. O’Connor & Qi-Xiang Li. (2023) HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models. Scientific Reports 13:1.
Crossref
Crossref
Olamide Tosin Olaoba, Kehinde Sulaimon Ayinde, Olubodun Michael Lateef, Michael Olawale Akintubosun, Khadijat Ayodeji Lawal & Temitope Isaac Adelusi. (2023) Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy. Critical Reviews in Oncology/Hematology 184, pages 103939.
Crossref
Crossref
Zi-Han Ye, Wei-Bang Yu, Mu-Yang Huang, Jun Chen & Jin-Jian Lu. (2023) Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B 13:4, pages 1467-1487.
Crossref
Crossref
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang & Wenzhi Tian. (2022) IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37:3, pages 695-698.
Crossref
Crossref
Longchao Liu & Jiahui Chen. (2023) Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review 2:6, pages 555-569.
Crossref
Crossref
Hua Yang, Yang Xun & Hua You. (2023) The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomarker Research 11:1.
Crossref
Crossref
Pooya Farhangnia, Ali-Akbar Delbandi, Maryam Sadri & Mahzad Akbarpour. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
46
.
Binglei Zhang, Wei Li, Dandan Fan, Wenzhi Tian, Jian Zhou, Zhenyu Ji & Yongping Song. (2022)
Advances in the study of
CD47
‐based bispecific antibody in cancer immunotherapy
. Immunology 167:1, pages 15-27.
Crossref
Crossref
Hui-Ting Bian, Yi-Wen Shen, Yu-Dong Zhou, Dale G. Nagle, Ying-Yun Guan, Wei-Dong Zhang & Xin Luan. (2022) CD47: Beyond an immune checkpoint in cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188771.
Crossref
Crossref
Wei Li, Fang Wang, Rongqun Guo, Zhilei Bian & Yongping Song. (2022) Targeting macrophages in hematological malignancies: recent advances and future directions. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Renée Bouwstra, Tom van Meerten & Edwin Bremer. (2022) CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies. Clinical and Translational Medicine 12:8.
Crossref
Crossref
Chilam Chan, Marta Lustig, Niklas Baumann, Thomas Valerius, Geert van Tetering & Jeanette H. W. Leusen. (2022) Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?. Frontiers in Immunology 13.
Crossref
Crossref
Julia Harwardt, Jan P. Bogen, Stefania C. Carrara, Michael Ulitzka, Julius Grzeschik, Björn Hock & Harald Kolmar. (2022) A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization. Frontiers in Immunology 13.
Crossref
Crossref
Fabien Thoreau & Vijay Chudasama. (2022) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 3:2, pages 140-169.
Crossref
Crossref
Susan Moradinasab, Atieh Pourbagheri-Sigaroodi, Seyed H. Ghaffari & Davood Bashash. (2022) Targeting macrophage-mediated tumor cell phagocytosis: An overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy. International Immunopharmacology 103, pages 108499.
Crossref
Crossref
Xu Cao, Seigmund W.T. Lai, Siqi Chen, Sadira Wang & Mingye Feng. 2022. One, No One, One Hundred Thousand - The Multifaceted Role of Macrophages in Health and Disease - Part B. One, No One, One Hundred Thousand - The Multifaceted Role of Macrophages in Health and Disease - Part B
61
108
.
Anujan Ramesh & Ashish A. Kulkarni. 2022. Systemic Drug Delivery Strategies. Systemic Drug Delivery Strategies
83
115
.
Yu-Chi Chen, Wei Shi, Jia-Jie Shi & Jin-Jian Lu. (2021) Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. Journal of Cancer Research and Clinical Oncology 148:1, pages 1-14.
Crossref
Crossref
Zhixin Cyrillus Tan, Brian T Orcutt-Jahns & Aaron S Meyer. (2021) A quantitative view of strategies to engineer cell-selective ligand binding. Integrative Biology 13:11, pages 269-282.
Crossref
Crossref
Nazli Dizman & Elizabeth I. Buchbinder. (2021) Cancer Therapy Targeting CD47/SIRPα. Cancers 13:24, pages 6229.
Crossref
Crossref
Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast, Andreas Humpe, Irmela Jeremias, Marion Subklewe, Nadja C. Fenn & Karl-Peter Hopfner. (2021) SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Madelyn Espinosa-Cotton & Nai-Kong V. Cheung. (2021) Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. Frontiers in Oncology 11.
Crossref
Crossref
Belén Blanco, Carmen Domínguez-Alonso & Luis Alvarez-Vallina. (2021) Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. Clinical Cancer Research 27:20, pages 5457-5464.
Crossref
Crossref
Yan Yang, Zheng Yang & Yun Yang. (2021) Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy. Frontiers in Immunology 12.
Crossref
Crossref
Chaoyu Wang, Chengtao Sun, Mengzhen Li, Bing Xia, Yi Wang, Li Zhang, Yanyan Zhang, Juan Wang, Feifei Sun, Suying Lu, Jia Zhu, Junting Huang & Yizhuo Zhang. (2020) Novel fully human anti‐CD47 antibodies stimulate phagocytosis and promote elimination of AML cells. Journal of Cellular Physiology 236:6, pages 4470-4481.
Crossref
Crossref
Qian‐Ni Ye, Yue Wang, Song Shen, Cong‐Fei Xu & Jun Wang. (2021) Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy. Advanced Healthcare Materials 10:11.
Crossref
Crossref
Zheng Tian, Ming Liu, Ya Zhang & Xin Wang. (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Zihao Li, Yue Li, Jing Gao, Yilin Fu, Peiyan Hua, Yingying Jing, Mingjun Cai, Hongda Wang & Ti Tong. (2021) The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sciences 273, pages 119150.
Crossref
Crossref
Siqi Chen, Seigmund W. T. Lai, Christine E. Brown & Mingye Feng. (2021) Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri & Fazel Shokri. (2021) A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. Frontiers in Immunology 11.
Crossref
Crossref
嘉欣 李. (2021) Application of CD47 Inhibitor in Tumor Therapy. Pharmacy Information 10:03, pages 129-137.
Crossref
Crossref
Xuefei Zhou, Xiangrui Liu & Leaf Huang. (2020) Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials 31:5, pages 2006220.
Crossref
Crossref
Entsar Eladl, Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Rumina Musani, Wenming Chen, Aijun Liu & Hong Chang. (2020) Role of CD47 in Hematological Malignancies. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Yongheng Shu & Ping Cheng. (2020) Targeting tumor-associated macrophages for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188434.
Crossref
Crossref
Fenglan Wu, Yangsheng Qiu & Yuhong Xu. (2020) A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. Cancer Immunology, Immunotherapy 69:12, pages 2561-2569.
Crossref
Crossref
Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer & Valerie R. Wiersma. (2020) The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences 21:21, pages 7820.
Crossref
Crossref
Yuqiong Xia, Lang Rao, Huimin Yao, Zhongliang Wang, Pengbo Ning & Xiaoyuan Chen. (2020) Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Advanced Materials 32:40.
Crossref
Crossref
Lamin B. Cham, Tom Adomati, Fanghui Li, Murtaza Ali & Karl S. Lang. (2020) CD47 as a Potential Target to Therapy for Infectious Diseases. Antibodies 9:3, pages 44.
Crossref
Crossref
Ridong Feng, Hai Zhao, Jianguo Xu & Chongyang Shen. (2020) CD47: the next checkpoint target for cancer immunotherapy. Critical Reviews in Oncology/Hematology 152, pages 103014.
Crossref
Crossref
Meike E.W. Logtenberg, Ferenc A. Scheeren & Ton N. Schumacher. (2020) The CD47-SIRPα Immune Checkpoint. Immunity 52:5, pages 742-752.
Crossref
Crossref
AbdelAziz R Jalil, Jason C Andrechak & Dennis E Discher. (2020) Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function. Antibody Therapeutics 3:2, pages 80-94.
Crossref
Crossref
Adarsh Mishra, Ishant Kataria & Sujit Nair. (2020) Pharmacokinetics and Systems Pharmacology of Anti-CD47 Macrophage Immune Checkpoint Inhibitor Hu5F9-G4. Current Pharmacogenomics and Personalized Medicine 17:1, pages 14-24.
Crossref
Crossref
Rui Shi, Yan Chai, Xiaomin Duan, Xiaoshan Bi, Qingrui Huang, Qihui Wang, Shuguang Tan, George F. Gao, Jianhua Zhu & Jinghua Yan. (2020) The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Seyed Mohammad Gheibi Hayat, Vanessa Bianconi, Matteo Pirro, Mahmoud R. Jaafari, Mahdi Hatamipour & Amirhossein Sahebkar. (2019) CD47: role in the immune system and application to cancer therapy. Cellular Oncology 43:1, pages 19-30.
Crossref
Crossref
Wenting Zhang, Qinghua Huang, Weiwei Xiao, Yue Zhao, Jiang Pi, Huan Xu, Hongxia Zhao, Junfa Xu, Colin E. Evans & Hua Jin. (2020) Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Frontiers in Immunology 11.
Crossref
Crossref
Amy J. Petty & Yiping Yang. (2019) Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies. Cells 8:12, pages 1526.
Crossref
Crossref
Iris Koopmans, Mark A.J.M. Hendriks, Robert J. van Ginkel, Douwe F. Samplonius, Edwin Bremer & Wijnand Helfrich. (2019) Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. Journal of Investigative Dermatology 139:11, pages 2343-2351.e3.
Crossref
Crossref
Mingye Feng, Wen Jiang, Betty Y. S. Kim, Cheng Cheng Zhang, Yang-Xin Fu & Irving L. Weissman. (2019) Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer 19:10, pages 568-586.
Crossref
Crossref
Frans V. Suurs, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries & Derk Jan A. de Groot. (2019) A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacology & Therapeutics 201, pages 103-119.
Crossref
Crossref
Raoufeh Ahamadi-Fesharaki, Abolfazl Fateh, Farzam Vaziri, Ghasem Solgi, Seyed Davar Siadat, Fereidoun Mahboudi & Fatemeh Rahimi-Jamnani. (2019) Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Molecular Therapy - Oncolytics 14, pages 38-56.
Crossref
Crossref
Hongcheng Yang, Ruoyang Shao, Hongxin Huang, Xinlong Wang, Zhili Rong & Ying Lin. (2019) Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis. Cancer Medicine 8:9, pages 4245-4253.
Crossref
Crossref
Haichao Tang, Yan Liu, Zhaojin Yu, Mingli Sun, Lu Lin, Wensi Liu, Qiang Han, Minjie Wei & Ying Jin. (2019) The Analysis of Key Factors Related to ADCs Structural Design. Frontiers in Pharmacology 10.
Crossref
Crossref
Lijun Xu, Shanlong Wang, Jie Li & Bingyu Li. (2019) CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies. Biochemical and Biophysical Research Communications 509:3, pages 739-745.
Crossref
Crossref
Jin Zhang, Shenhe Jin, Xiaojun Guo & Wenbin Qian. (2018) Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy. Journal of International Medical Research 46:11, pages 4418-4426.
Crossref
Crossref
Atlantis Russ, Anh B. Hua, William R. Montfort, Bushra Rahman, Irbaz Bin Riaz, Muhammad Umar Khalid, Jennifer S. Carew, Steffan T. Nawrocki, Daniel Persky & Faiz Anwer. (2018) Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. Blood Reviews 32:6, pages 480-489.
Crossref
Crossref
Xuyao Zhang, Jiajun Fan & Dianwen Ju. (2018) Insights into CD47/SIRPα axis-targeting tumor immunotherapy. Antibody Therapeutics 1:2, pages 37-42.
Crossref
Crossref
Bing Tong & Mengzhao Wang. (2018) CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Future Oncology 14:21, pages 2179-2188.
Crossref
Crossref
Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, Anne Papaioannou, Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Bruno Daubeuf, Laura Cons, Lucile Broyer, Matilde D'Asaro, Thomas Matthes, Simon LeGallou, Thierry Fest, Karin Tarte, Robert K. Clarke Hinojosa, Eulàlia Genescà Ferrer, José María Ribera, Aditi Dey, Katharine Bailey, Adele K. Fielding, Linda Eissenberg, Julie Ritchey, Michael Rettig, John F. DiPersio, Marie H. Kosco-Vilbois, Krzysztof Masternak, Nicolas Fischer, Limin Shang & Walter G. Ferlin. (2018) Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics 17:8, pages 1739-1751.
Crossref
Crossref
Yan Lin, Jun-Long Zhao, Qi-Jun Zheng, Xun Jiang, Jiao Tian, Shi-Qian Liang, Hong-Wei Guo, Hong-Yan Qin, Ying-Min Liang & Hua Han. (2018) Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression. Frontiers in Immunology 9.
Crossref
Crossref
Yun Yang, Rui Guo, Qi Chen, Youxun Liu, Pengfei Zhang, Ziheng Zhang, Xi Chen & Tianyun Wang. (2018) A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index. Biotechnology Letters 40:5, pages 789-795.
Crossref
Crossref
Khaled Seidi, Heidi A. Neubauer, Richard Moriggl, Rana Jahanban-Esfahlan & Tahereh Javaheri. (2018) Tumor target amplification: Implications for nano drug delivery systems. Journal of Controlled Release 275, pages 142-161.
Crossref
Crossref
Paul J. Carter & Greg A. Lazar. (2017) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery 17:3, pages 197-223.
Crossref
Crossref
Meher Majety, Valeria Runza, Christian Lehmann, Sabine Hoves & Carola H. Ries. (2018) A drug development perspective on targeting tumor-associated myeloid cells. The FEBS Journal 285:4, pages 763-776.
Crossref
Crossref
Elie Dheilly, Stefano Majocchi, Valéry Moine, Gérard Didelot, Lucile Broyer, Sébastien Calloud, Pauline Malinge, Laurence Chatel, Walter Ferlin, Marie Kosco-Vilbois, Nicolas Fischer & Krzysztof Masternak. (2018) Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity. Antibodies 7:1, pages 3.
Crossref
Crossref
Xiaolong Zhang, Yuanyuan Yang, Dongmei Fan & Dongsheng Xiong. (2017) The development of bispecific antibodies and their applications in tumor immune escape. Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Thorsten Gantke, Michael Weichel, Carmen Herbrecht, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Markus Eser, Thomas Müller, Remko Griep, Vera Molkenthin, Eugene A Zhukovsky & Martin Treder. (2017) Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering, Design and Selection 30:9, pages 673-684.
Crossref
Crossref
Sandra Gallagher, Sean Turman, Kristen Lekstrom, Susan Wilson, Ronald Herbst & Yue Wang. (2017) CD47 limits antibody dependent phagocytosis against non-malignant B cells. Molecular Immunology 85, pages 57-65.
Crossref
Crossref
Kipp Weiskopf. (2017) Cancer immunotherapy targeting the CD47/SIRPα axis. European Journal of Cancer 76, pages 100-109.
Crossref
Crossref
Hanke L. Matlung, Katka Szilagyi, Neil A. Barclay & Timo K. van den Berg. (2017) The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunological Reviews 276:1, pages 145-164.
Crossref
Crossref
E C Pietsch, J Dong, R Cardoso, X Zhang, D Chin, R Hawkins, T Dinh, M Zhou, B Strake, P-H Feng, M Rocca, C Dos Santos, X Shan, G Danet-Desnoyers, F Shi, E Kaiser, H J Millar, S Fenton, R Swanson, J A Nemeth & R M Attar. (2017) Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer Journal 7:2, pages e536-e536.
Crossref
Crossref
Laia Pascual Ponce, Nadja C. Fenn, Nadine Moritz, Christina Krupka, Jan-Hendrik Kozik, Kirsten Lauber, Marion Subklewe & Karl-Peter Hopfner. (2017) SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget 8:7, pages 11284-11301.
Crossref
Crossref
S S Hoseini & N K Cheung. (2017) Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer Journal 7:2, pages e522-e522.
Crossref
Crossref
Elie Dheilly, Valéry Moine, Lucile Broyer, Susana Salgado-Pires, Zoë Johnson, Anne Papaioannou, Laura Cons, Sébastien Calloud, Stefano Majocchi, Robert Nelson, François Rousseau, Walter Ferlin, Marie Kosco-Vilbois, Nicolas Fischer & Krzysztof Masternak. (2017) Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. Molecular Therapy 25:2, pages 523-533.
Crossref
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017.
289
383
.
Emily C. Piccione, Silvia Juarez, Serena Tseng, Jie Liu, Melissa Stafford, Cyndhavi Narayanan, Lijuan Wang, Kipp Weiskopf & Ravindra Majeti. (2016) SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clinical Cancer Research 22:20, pages 5109-5119.
Crossref
Crossref
Yaghoub Safdari, Vahideh Ahmadzadeh & Safar Farajnia. (2016) CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Investigational New Drugs 34:4, pages 497-512.
Crossref
Crossref
Joanie Del Bano, Patrick Chames, Daniel Baty & Brigitte Kerfelec. (2015) Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. Antibodies 5:1, pages 1.
Crossref
Crossref
Seongwan Jo, Nicholas Cronin, Ni Putu Dewi Nurmalasari, Jason G. Kerkvliet, Elizabeth M. Bailey, Robert B. Anderson, Brandon L. Scott & Adam D. Hoppe. (2021) IgG Surface Mobility Promotes Antibody Dependent Cellular Phagocytosis by Syk and Arp2/3 Mediated Reorganization of Macrophage FcγRs. SSRN Electronic Journal.
Crossref
Crossref